Drugs / ESR 1150 CL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02209688 | Feb → Mar 2000 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02183259 | Nov → Dec 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESR 1150 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02183259 ↗ |
| Route | Oral | “ESR 1150 CL, Capsule, oral” NCT02183259 ↗ |